These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 16144953

  • 1. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3'-triiodothyronine therapy.
    Appelhof BC, Peeters RP, Wiersinga WM, Visser TJ, Wekking EM, Huyser J, Schene AH, Tijssen JG, Hoogendijk WJ, Fliers E.
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6296-9. PubMed ID: 16144953
    [Abstract] [Full Text] [Related]

  • 2. Combination L-T3 and L-T4 therapy for hypothyroidism.
    Wartofsky L.
    Curr Opin Endocrinol Diabetes Obes; 2013 Oct; 20(5):460-6. PubMed ID: 23974776
    [Abstract] [Full Text] [Related]

  • 3. Polymorphisms in the brain-specific thyroid hormone transporter OATP1C1 are associated with fatigue and depression in hypothyroid patients.
    van der Deure WM, Appelhof BC, Peeters RP, Wiersinga WM, Wekking EM, Huyser J, Schene AH, Tijssen JG, Hoogendijk WJ, Visser TJ, Fliers E.
    Clin Endocrinol (Oxf); 2008 Nov; 69(5):804-11. PubMed ID: 18410547
    [Abstract] [Full Text] [Related]

  • 4. No Effect of the Thr92Ala Polymorphism of Deiodinase-2 on Thyroid Hormone Parameters, Health-Related Quality of Life, and Cognitive Functioning in a Large Population-Based Cohort Study.
    Wouters HJ, van Loon HC, van der Klauw MM, Elderson MF, Slagter SN, Kobold AM, Kema IP, Links TP, van Vliet-Ostaptchouk JV, Wolffenbuttel BH.
    Thyroid; 2017 Feb; 27(2):147-155. PubMed ID: 27786042
    [Abstract] [Full Text] [Related]

  • 5. DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient Patients.
    Castagna MG, Dentice M, Cantara S, Ambrosio R, Maino F, Porcelli T, Marzocchi C, Garbi C, Pacini F, Salvatore D.
    J Clin Endocrinol Metab; 2017 May 01; 102(5):1623-1630. PubMed ID: 28324063
    [Abstract] [Full Text] [Related]

  • 6. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism.
    Siegmund W, Spieker K, Weike AI, Giessmann T, Modess C, Dabers T, Kirsch G, Sänger E, Engel G, Hamm AO, Nauck M, Meng W.
    Clin Endocrinol (Oxf); 2004 Jun 01; 60(6):750-7. PubMed ID: 15163340
    [Abstract] [Full Text] [Related]

  • 7. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients.
    Panicker V, Saravanan P, Vaidya B, Evans J, Hattersley AT, Frayling TM, Dayan CM.
    J Clin Endocrinol Metab; 2009 May 01; 94(5):1623-9. PubMed ID: 19190113
    [Abstract] [Full Text] [Related]

  • 8. Pathophysiological relevance of deiodinase polymorphism.
    Bianco AC, Kim BS.
    Curr Opin Endocrinol Diabetes Obes; 2018 Oct 01; 25(5):341-346. PubMed ID: 30063552
    [Abstract] [Full Text] [Related]

  • 9. Thyroxine vs thyroxine plus triiodothyronine in treatment of hypothyroidism after thyroidectomy for Graves' disease.
    Bunevicius R, Jakuboniene N, Jurkevicius R, Cernicat J, Lasas L, Prange AJ.
    Endocrine; 2002 Jul 01; 18(2):129-33. PubMed ID: 12374459
    [Abstract] [Full Text] [Related]

  • 10. Fasting-induced increase in type II iodothyronine deiodinase activity and messenger ribonucleic acid levels is not reversed by thyroxine in the rat hypothalamus.
    Diano S, Naftolin F, Goglia F, Horvath TL.
    Endocrinology; 1998 Jun 01; 139(6):2879-84. PubMed ID: 9607797
    [Abstract] [Full Text] [Related]

  • 11. Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat.
    Escobar-Morreale HF, del Rey FE, Obregón MJ, de Escobar GM.
    Endocrinology; 1996 Jun 01; 137(6):2490-502. PubMed ID: 8641203
    [Abstract] [Full Text] [Related]

  • 12. The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe.
    de Jong FJ, Peeters RP, den Heijer T, van der Deure WM, Hofman A, Uitterlinden AG, Visser TJ, Breteler MM.
    J Clin Endocrinol Metab; 2007 Feb 01; 92(2):636-40. PubMed ID: 17105838
    [Abstract] [Full Text] [Related]

  • 13. A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters.
    Peeters RP, van den Beld AW, Attalki H, Toor Hv, de Rijke YB, Kuiper GG, Lamberts SW, Janssen JA, Uitterlinden AG, Visser TJ.
    Am J Physiol Endocrinol Metab; 2005 Jul 01; 289(1):E75-81. PubMed ID: 15727947
    [Abstract] [Full Text] [Related]

  • 14. Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditis.
    Heemstra KA, Hoftijzer HC, van der Deure WM, Peeters RP, Fliers E, Appelhof BC, Wiersinga WM, Corssmit EP, Visser TJ, Smit JW.
    Clin Endocrinol (Oxf); 2009 Aug 01; 71(2):279-83. PubMed ID: 19018782
    [Abstract] [Full Text] [Related]

  • 15. Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial.
    Appelhof BC, Fliers E, Wekking EM, Schene AH, Huyser J, Tijssen JG, Endert E, van Weert HC, Wiersinga WM.
    J Clin Endocrinol Metab; 2005 May 01; 90(5):2666-74. PubMed ID: 15705921
    [Abstract] [Full Text] [Related]

  • 16. Type II deiodinase polymorphisms and serum thyroid hormone levels in patients with mild cognitive impairment.
    Luo M, Zhou XH, Zou T, Keyim K, Dong LM.
    Genet Mol Res; 2015 May 22; 14(2):5407-16. PubMed ID: 26125736
    [Abstract] [Full Text] [Related]

  • 17. Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism.
    Wekking EM, Appelhof BC, Fliers E, Schene AH, Huyser J, Tijssen JG, Wiersinga WM.
    Eur J Endocrinol; 2005 Dec 22; 153(6):747-53. PubMed ID: 16322379
    [Abstract] [Full Text] [Related]

  • 18. The role of type II deiodinase polymorphisms in clinical management of hypothyroid patients treated with levothyroxine.
    Al-azzam SI, Alkhateeb AM, Al-Azzeh O, Alzoubi KH, Khabour OF.
    Exp Clin Endocrinol Diabetes; 2013 May 22; 121(5):300-5. PubMed ID: 23329579
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Do we need still more trials on T4 and T3 combination therapy in hypothyroidism?
    Wiersinga WM.
    Eur J Endocrinol; 2009 Dec 22; 161(6):955-9. PubMed ID: 19808902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.